Phase 1/2 study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: overall safety at the recommended Phase 2 dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)

Maria Alsina, Andrea Varga, Alessio Amatu, Jan H.M. Schellens, Els Witteveen, Valentina Boni, Victor Moreno, Paolo Nuciforo, Aurelia de Vries Schultink, Kees Bol, Afrodite Lourbakos, Marina Magin Ferrer, and Ernesto Wasserman. Poster presented at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany.